ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
Thomas Powles,Laurence Albiges,Axel Bex,Axel Bex,Viktor Grünwald,Camillo Porta,Giuseppe Procopio,Manuela Schmidinger,Cristina Suarez,G. De Velasco +9 more
About:
This article is published in Annals of Oncology.The article was published on 2021-09-23 and is currently open access. It has received 89 citations till now. The article focuses on the topics: Guideline & Renal cell carcinoma.read more
Citations
More filters
Journal ArticleDOI
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Robert J. Motzer,Thomas Powles,Mauricio Burotto,Bernard Escudier,Maria T Bourlon,Amishi Yogesh Shah,Cristina Sáez,Alketa Hamzaj,Camillo Porta,Christopher Hocking,Elizabeth R. Kessler,Howard Gurney,Yoshihiko Tomita,Jens Bedke,Joshua Zhang,Burcin Simsek,Christian Scheffold,Andrea B. Apolo,Toni K. Choueiri +18 more
TL;DR: The CheckMate 9ER trial as mentioned in this paper showed that nivolumab plus cabozantinib showed superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously untreated advanced renal cell carcinoma.
Journal ArticleDOI
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
TL;DR: A randomized, double-blind, multicentre, phase 3 trial conducted in 215 centres in 28 countries as mentioned in this paper was conducted to determine if adjuvant atezolizumab (vs placebo) delayed recurrence in patients with an increased risk of recurrence after resection.
Journal ArticleDOI
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Yann Vano,Reza Elaidi,Mostefa Bennamoun,Christine Chevreau,Delphine Borchiellini,Diane Pannier,Denis Maillet,Marine Gross-Goupil,Christophe Tournigand,Brigitte Laguerre,Philippe Barthélémy,Elodie Coquan,Gwenaelle Gravis,Nadine Houede,Mathilde Cancel,Olivier Huillard,Philippe Beuzeboc,Laure Fournier,Arnaud Mejean,Xavier Cathelineau,Nicolas Doumerc,Philippe Paparel,Jean-Christophe Bernhard,C. De La Taille,Karim Bensalah,T. Tricard,Thibaut Waeckel,Géraldine Pignot,E. Braychenko,Stefano Caruso,Cheng-Ming Sun,Virginie Verkarre,Guillaume Lacroix,Marco Moreira,Maxime Meylan,Antoine Bougouïn,Letuan Phan,Christelle Thibault-Carpentier,Jessica Zucman-Rossi,Wolf H. Fridman,Catherine Sautès-Fridman,Stéphane Oudard +41 more
TL;DR: In this article , the authors evaluated treatment efficacy and tolerability of nivolumab, nivlumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors (VEGFR-TKIs) in patients according to tumour molecular groups.
Journal ArticleDOI
Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma
Pablo Álvarez Ballesteros,Jesús Chamorro,María San Román-Gil,Javier Pozas,Victoria Gómez Dos Santos,Álvaro Ruiz Granados,Enrique Grande,Teresa Alonso-Gordoa,Javier Molina-Cerrillo +8 more
TL;DR: In this article, the authors summarize the insights of these molecular alterations to understand the resistance pathways related to the treatment with TKI and immune checkpoint inhibitors (ICIs), and include additional information on novel approaches that are currently under research to overcome these resistance alterations in preclinical studies and early phase clinical trials.
Journal ArticleDOI
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Robert J. Motzer,Camillo Porta,Boris Alekseev,Sun Young Rha,Toni K. Choueiri,M.J. Méndez-Vidal,Sung-Hoo Hong,Anil Kapoor,Jeffrey C. Goh,Masatoshi Eto,Lee Bennett,Jinyi Wang,Jie Pan,Todd L. Saretsky,Rodolfo F. Perini,Cixin He,Kalgi Mody,David Cella +17 more
TL;DR: In this article , a phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma.
References
More filters
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more
TL;DR: Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bernard Escudier,Camillo Porta,Manuela Schmidinger,Nathalie Rioux-Leclercq,Axel Bex,Vincent Khoo,Vincent Khoo,V. Gruenvald,Alan Horwich +8 more
TL;DR: RCC appears to be more common in patients with obesity, end-stage renal failure, acquired renal cystic disease and tuber-ous sclerosis, and severalautosomal dominant syndromes are described, each with a dis-tinct genetic basis and phenotype.
Related Papers (3)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer,Konstantin Penkov,John B. A. G. Haanen,Brian I. Rini,Laurence Albiges,Matthew T. Campbell,Balaji Venugopal,Christian Kollmannsberger,Sylvie Negrier,Motohide Uemura,Jae L. Lee,Aleksandr Vasiliev,Wilson H. Miller,Howard Gurney,Manuela Schmidinger,James Larkin,Michael B. Atkins,Jens Bedke,Boris Alekseev,Jing Wang,Mariangela Mariani,Paul B. Robbins,Aleksander Chudnovsky,Camilla Fowst,Subramanian Hariharan,Bo Huang,Alessandra di Pietro,Toni K. Choueiri +27 more
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more